Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Flinn

Showing results (921-930 of 1,038) with videos related to

Pageof 104
Sort By:
Blood Advances|January 4, 2018
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphomaSven de Vos, Nina D Wagner-Johnston, Steven E Coutre, et al.
Hemasphere|June 19, 2026
Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphomaDavid Belada, Faithlore P Gardner, Ana C de Oliveira, et al.
Blood Advances|March 15, 2025
Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomesMarek Trněný, Laura Maria Fogliato, Faithlore Gardner, et al.
Leukemia|February 4, 2016
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trialA Hochhaus, G Saglio, T P Hughes, et al.
Plos One|February 25, 2021
Higher SARS-CoV-2 seroprevalence in workers with lower socioeconomic status in Cape Town, South AfricaJane Alexandra Shaw, Maynard Meiring, Tracy Cummins, et al.
British Journal of Haematology|June 13, 2002
Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experienceB Douglas Smith, Richard J Jones, Shing M Lee, et al.
Leukemia & Lymphoma|April 11, 2014
Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphomaKristen N Ganjoo, Sven de Vos, Brad L Pohlman, et al.
American Journal of Hematology|December 2, 2010
Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acidJames R Berenson, Ori Yellin, John Crowley, et al.
JAMA Oncology|December 23, 2021
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell CarcinomaRobert J Motzer, Thomas Powles, Michael B Atkins, et al.
Leukemia & Lymphoma|October 3, 2018
Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER studyJeff P Sharman, Andres Forero-Torres, Luciano J Costa, et al.
Pageof 104

Showing results (921-930 of 1,038) with videos related to

Sort By:
Pageof 104
Blood Advances|January 4, 2018
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphomaSven de Vos, Nina D Wagner-Johnston, Steven E Coutre, et al.
Hemasphere|June 19, 2026
Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphomaDavid Belada, Faithlore P Gardner, Ana C de Oliveira, et al.
Blood Advances|March 15, 2025
Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomesMarek Trněný, Laura Maria Fogliato, Faithlore Gardner, et al.
Leukemia|February 4, 2016
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trialA Hochhaus, G Saglio, T P Hughes, et al.
Plos One|February 25, 2021
Higher SARS-CoV-2 seroprevalence in workers with lower socioeconomic status in Cape Town, South AfricaJane Alexandra Shaw, Maynard Meiring, Tracy Cummins, et al.
British Journal of Haematology|June 13, 2002
Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experienceB Douglas Smith, Richard J Jones, Shing M Lee, et al.
Leukemia & Lymphoma|April 11, 2014
Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphomaKristen N Ganjoo, Sven de Vos, Brad L Pohlman, et al.
American Journal of Hematology|December 2, 2010
Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acidJames R Berenson, Ori Yellin, John Crowley, et al.
JAMA Oncology|December 23, 2021
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell CarcinomaRobert J Motzer, Thomas Powles, Michael B Atkins, et al.
Leukemia & Lymphoma|October 3, 2018
Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER studyJeff P Sharman, Andres Forero-Torres, Luciano J Costa, et al.
Pageof 104